Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06605404 · ClinicalTrials.gov registry record
Pan-tumor MRD Study
A clinical trial of Esophageal Cancer and NSCLC (Non-small Cell Lung Cancer), sponsored by Paradigm Health.
- Recruiting
- Registry status
- 1,350
- Enrollment target
- 2
- Study locations
NCT06605404 is a study of Esophageal Cancer and NSCLC (Non-small Cell Lung Cancer) that is actively recruiting participants, run by Paradigm Health. The registered enrollment target is 1,350 participants, above the 488-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (177% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT06605404, a study of Esophageal Cancer and NSCLC (Non-small Cell Lung Cancer), is actively recruiting participants, sponsored by Paradigm Health.
- RECRUITING
- Registry status
- 1,350 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, for example, to improve cancer detection and to assess the risk of cancer coming back. Participants will receive routine standard of care from their doctor and their involvement is expected to last for approximately five and a half (5.5) years.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST blood and tissue samples
- OTHER blood and tissue samples
Study Locations (2)
California
- Medical Oncology Associates of San Diego - San Diego
Ohio
- Taylor Cancer Research Center - Maumee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,350 participants |
| Start Date | 2025-01-08 |
| Est. Completion | 2032-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06605404
The ClinicalTrials.gov registry entry for NCT06605404 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,350 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 488-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (177% higher). The listed sponsor is Paradigm Health, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Esophageal Cancer appearing as the primary indexed condition, and to 2 interventions - of which blood and tissue samples is the first listed.
NCT06605404 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Ohio.
Frequently Asked Questions
What is clinical trial NCT06605404 about?
NCT06605404 is a clinical study titled "Pan-tumor MRD Study". The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, fo...
What is the current status of trial NCT06605404?
This trial is currently recruiting. The enrollment target is 1,350 participants. The study started on 2025-01-08. Estimated completion is 2032-04.
What conditions does trial NCT06605404 study?
This clinical trial studies the following conditions: Esophageal Cancer, NSCLC (Non-small Cell Lung Cancer), Melanoma (Skin Cancer), Muscle Invasive Bladder Urothelial Carcinoma, Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma.
What interventions are being tested in trial NCT06605404?
The interventions under investigation include: blood and tissue samples (DIAGNOSTIC_TEST), blood and tissue samples (OTHER).
Who is sponsoring clinical trial NCT06605404?
This trial is sponsored by Paradigm Health, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06605404 being conducted?
This trial has 2 study locations across California, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Registry for Esophageal and Gastroesophageal Junction Cancer
RECRUITING
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
Retrospective Review of Esophageal Cancer at MSKCC
RECRUITING
-
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.